Long-term morbidity of respiratory viral infections during chemotherapy in children with leukaemia.
cancer survivors
child
neoplasms
respiratory function tests
respiratory traction infections
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
02
02
2018
accepted:
06
06
2019
pubmed:
9
8
2019
medline:
22
4
2020
entrez:
9
8
2019
Statut:
ppublish
Résumé
Respiratory viruses are a common cause of infection in immunosuppressed children undergoing cancer therapy. Pulmonary sequelae have been documented following respiratory viral infections (RVIs) in hematopoietic stem cell transplant (HSCT) recipients; however potential late effects in children undergoing nonmyeloablative chemotherapy have not been investigated. To evaluate the long-term pulmonary morbidity of respiratory viral infections during chemotherapy in children with acute lymphoblastic leukemia (ALL). Childhood ALL survivors, aged 7 to 18 years, greater than 6 months posttreatment were recruited. Exclusion criteria included HSCT or proven bacterial/fungal respiratory infection during treatment. Subjects were classified into "viral" or "control" groups according to retrospective medical records that documented the presence of laboratory-proven RVIs during chemotherapy. Symptom questionnaires (Liverpool, ISAAC) and lung function testing (spirometry, plethysmography, diffusing capacity, forced oscillation technique to ATS/ERS standards) were then performed cross-sectionally at the time of recruitment. Fifty-four patients (31 viral, 23 control) were recruited: median (range) age 11.2 (7.2-18.1) years, and at 4.9 (0.5-13) years posttherapy. Abnormalities were detected in 17 (31%) individuals (8 viral, 9 control), with the most common being DLCO impairment (3 viral, 4 control) and reduced respiratory reactance at 5 Hz (5 viral, 6 control). Children with RVIs during chemotherapy reported more current respiratory symptoms, particularly wheeze (odds ratio [OR], 3.0; 95% confidence interval [CI]: 0.9-10.0; P = .09) and cough (OR, 2.7; 95% CI: 0.8-9.5; P = .11). No differences in lung function tests were observed between the two groups. Our study found children with RVIs during chemotherapy developed more long-term respiratory symptoms than controls; however, differences did not reach statistical significance. No differences in static lung function were found between the two groups. Overall, pulmonary abnormalities and/or significant ongoing respiratory symptoms were detected in nearly a third of ALL survivors treated without HSCT. Larger, prospective studies are warranted to evaluate the etiology and clinical significance of these findings.
Sections du résumé
BACKGROUND
Respiratory viruses are a common cause of infection in immunosuppressed children undergoing cancer therapy. Pulmonary sequelae have been documented following respiratory viral infections (RVIs) in hematopoietic stem cell transplant (HSCT) recipients; however potential late effects in children undergoing nonmyeloablative chemotherapy have not been investigated.
AIM
To evaluate the long-term pulmonary morbidity of respiratory viral infections during chemotherapy in children with acute lymphoblastic leukemia (ALL).
METHODS
Childhood ALL survivors, aged 7 to 18 years, greater than 6 months posttreatment were recruited. Exclusion criteria included HSCT or proven bacterial/fungal respiratory infection during treatment. Subjects were classified into "viral" or "control" groups according to retrospective medical records that documented the presence of laboratory-proven RVIs during chemotherapy. Symptom questionnaires (Liverpool, ISAAC) and lung function testing (spirometry, plethysmography, diffusing capacity, forced oscillation technique to ATS/ERS standards) were then performed cross-sectionally at the time of recruitment.
RESULTS
Fifty-four patients (31 viral, 23 control) were recruited: median (range) age 11.2 (7.2-18.1) years, and at 4.9 (0.5-13) years posttherapy. Abnormalities were detected in 17 (31%) individuals (8 viral, 9 control), with the most common being DLCO impairment (3 viral, 4 control) and reduced respiratory reactance at 5 Hz (5 viral, 6 control). Children with RVIs during chemotherapy reported more current respiratory symptoms, particularly wheeze (odds ratio [OR], 3.0; 95% confidence interval [CI]: 0.9-10.0; P = .09) and cough (OR, 2.7; 95% CI: 0.8-9.5; P = .11). No differences in lung function tests were observed between the two groups.
CONCLUSIONS
Our study found children with RVIs during chemotherapy developed more long-term respiratory symptoms than controls; however, differences did not reach statistical significance. No differences in static lung function were found between the two groups. Overall, pulmonary abnormalities and/or significant ongoing respiratory symptoms were detected in nearly a third of ALL survivors treated without HSCT. Larger, prospective studies are warranted to evaluate the etiology and clinical significance of these findings.
Identifiants
pubmed: 31393087
doi: 10.1002/ppul.24456
pmc: PMC7167615
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1821-1829Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Med Pediatr Oncol. 1986;14(4):202-7
pubmed: 3747939
Med Pediatr Oncol. 1995 Apr;24(4):222-30
pubmed: 7700166
Pediatr Pulmonol. 2008 Dec;43(12):1193-7
pubmed: 18988256
Biol Blood Marrow Transplant. 2010 Jun;16(6):782-91
pubmed: 20060053
J Allergy Clin Immunol. 2015 Jul;136(1):81-86.e4
pubmed: 25910716
Pediatr Pulmonol. 2019 Nov;54(11):1821-1829
pubmed: 31393087
J Pediatr Hematol Oncol. 1997 Sep-Oct;19(5):399-417
pubmed: 9329461
Pediatr Infect Dis J. 2007 Aug;26(8):733-9
pubmed: 17848887
J Clin Virol. 2010 Mar;47(3):234-7
pubmed: 20056482
Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72
pubmed: 18565953
Pediatr Blood Cancer. 2016 Jul;63(7):1264-71
pubmed: 27002916
J Infect Dis. 2006 Jun 15;193(12):1619-25
pubmed: 16703503
JAMA. 2013 Jun 12;309(22):2371-2381
pubmed: 23757085
Blood. 2008 May 1;111(9):4477-89
pubmed: 18285545
Pediatr Infect Dis J. 2013 Mar;32(3):e99-e104
pubmed: 23190778
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2185-98
pubmed: 8520796
Cancer Res. 1965 Aug;25(7):997-1001
pubmed: 5843275
Pediatr Infect Dis J. 2008 Nov;27(11):974-80
pubmed: 18833026
Cancer. 2016 Mar 1;122(5):798-805
pubmed: 26700662
Med Pediatr Oncol. 1989;17(2):149-54
pubmed: 2704334
Leukemia. 2013 Jul;27(7):1497-503
pubmed: 23407458
Eur Respir J. 2003 Dec;22(6):1026-41
pubmed: 14680096
Respir Physiol Neurobiol. 2011 Jul 31;177(2):199-206
pubmed: 21320646
Br J Cancer. 1998 Jul;78(1):21-7
pubmed: 9662245
Leukemia. 2014 Dec;28(12):2336-43
pubmed: 24781017
Chest. 2014 Oct;146(4):974-981
pubmed: 24991854
N Engl J Med. 2013 Apr 11;368(15):1398-407
pubmed: 23534543
J Natl Cancer Inst. 2008 Oct 1;100(19):1368-79
pubmed: 18812549
Eur Respir J. 1995 Mar;8(3):483-91
pubmed: 7789502
Am J Respir Crit Care Med. 2003 Sep 15;168(6):633-9
pubmed: 12773328
Cancer. 2016 Dec 1;122(23):3687-3696
pubmed: 27504874
Pediatr Hematol Oncol. 2011 Aug;28(5):403-17
pubmed: 21728717
Pediatr Blood Cancer. 2005 Dec;45(7):945-51
pubmed: 16047356
Ann Am Thorac Soc. 2016 Sep;13(9):1448-9
pubmed: 27627472
J Allergy Clin Immunol. 2009 Apr;123(4):861-7.e1
pubmed: 19070356
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Chest. 1999 Nov;116(5):1163-7
pubmed: 10559071
Eur Respir J. 1997 Jun;10(6):1205-6
pubmed: 9192917